We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
- Authors
Carducci, Michael A; Musib, Luna; Kies, Merrill S; Pili, Roberto; Truong, Mylene; Brahmer, Julie R; Cole, Patricia; Sullivan, Rana; Riddle, Jeanne; Schmidt, Jill; Enas, Nathan; Sinha, Vikram; Thornton, Donald E; Herbst, Roy S
- Abstract
This phase I study was conducted to determine the recommended dose of enzastaurin, an oral protein kinase C beta (PKCbeta) inhibitor, for phase II trials. Secondary objectives were maximum-tolerated dose (MTD), pharmacokinetics (PK), toxicity, and response.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Vol 24, Issue 25, p4092
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.05.3447